This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

I read with interest the review article by Weitz and Bates¹ concerning new treatments for unstable angina and non–Q-wave myocardial infarction, which appeared in the March 27, 2000, issue of the ARCHIVES. I would like to comment about some aspects of the article.

With respect to low-molecular-weight heparins, only the Fragmin During Instability in Coronary Artery Disease (FRISC),² Fragmin in Unstable Coronary Artery Disease (FRIC),³ Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-Wave Coronary Events (ESSENCE),⁴ and Thrombolysis in Myocardial Infarction (TIMI) 11B⁵ studies were considered in this review, and the authors conclude in the "Comment" section that 1 low-molecular-weight heparin (enoxaparin) has shown benefit in patients with unstable angina or non–Q-wave myocardial infarction. Results of the TIMI 11B⁵ trial were published in October 1999, but, previously, in August 1999, the results of the FRISC II study⁶ were published, and, surprisingly, they were not analyzed by Weitz and Bates. Moreover, . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?